KR20060041254A - 퀴놀론 유도체 또는 그의 염 - Google Patents
퀴놀론 유도체 또는 그의 염 Download PDFInfo
- Publication number
- KR20060041254A KR20060041254A KR1020067001356A KR20067001356A KR20060041254A KR 20060041254 A KR20060041254 A KR 20060041254A KR 1020067001356 A KR1020067001356 A KR 1020067001356A KR 20067001356 A KR20067001356 A KR 20067001356A KR 20060041254 A KR20060041254 A KR 20060041254A
- Authority
- KR
- South Korea
- Prior art keywords
- lower alkyl
- compound
- substituted
- ethyl
- amino
- Prior art date
Links
- 0 CC(*)OCC(C(**)=*C1*=*)=C(C)C1=* Chemical compound CC(*)OCC(C(**)=*C1*=*)=C(C)C1=* 0.000 description 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/5765—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/60—Quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
- C07F9/650947—Six-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003278852 | 2003-07-24 | ||
| JPJP-P-2003-00278852 | 2003-07-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060041254A true KR20060041254A (ko) | 2006-05-11 |
Family
ID=34100788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067001356A KR20060041254A (ko) | 2003-07-24 | 2004-07-22 | 퀴놀론 유도체 또는 그의 염 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7488739B2 (fr) |
| EP (1) | EP1650192A4 (fr) |
| KR (1) | KR20060041254A (fr) |
| CN (1) | CN100471842C (fr) |
| CA (1) | CA2530352A1 (fr) |
| MX (1) | MXPA06000675A (fr) |
| WO (1) | WO2005009971A1 (fr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| EP1650192A4 (fr) * | 2003-07-24 | 2007-03-21 | Astellas Pharma Inc | Derive de quinolone ou sel de ce dernier |
| ME02970B (fr) | 2004-06-24 | 2018-07-20 | Vertex Pharma | Modulateurs de transporteurs de cassette de liaison a l ́ATP |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| JP2008094720A (ja) * | 2005-01-20 | 2008-04-24 | Astellas Pharma Inc | キノロン誘導体のプロドラッグ又はその塩 |
| GB0519758D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel process |
| JP5192389B2 (ja) * | 2005-12-05 | 2013-05-08 | メルク・シャープ・エンド・ドーム・コーポレイション | キノロンｍ１レセプター陽性アロステリックモジュレータ |
| US20090105272A1 (en) * | 2005-12-24 | 2009-04-23 | Grootenhuis Peter D J | Prodrugs of modulators of ABC transporters |
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| WO2007100657A2 (fr) | 2006-02-28 | 2007-09-07 | Merck & Co., Inc. | Inhibiteurs de l'histone désacétylase |
| ES2427247T3 (es) | 2006-03-13 | 2013-10-30 | Kyorin Pharmaceutical Co., Ltd. | Aminoquinolonas como inhibidores de GSK-3 |
| TWI391378B (zh) | 2006-03-16 | 2013-04-01 | Astellas Pharma Inc | 喹啉酮衍生物或其製藥學上可被容許之鹽 |
| JP2010037198A (ja) * | 2006-11-22 | 2010-02-18 | Astellas Pharma Inc | キノロン誘導体又はその製薬学的に許容される塩 |
| WO2008131134A1 (fr) * | 2007-04-17 | 2008-10-30 | Cylene Pharmaceuticals, Inc. | Composés hydrazides et leurs utilisations |
| WO2008133155A1 (fr) | 2007-04-19 | 2008-11-06 | Astellas Pharma Inc. | Composé hétérocyclique bicyclique |
| MX2009011089A (es) | 2007-04-23 | 2009-10-30 | Sanofi Aventis | Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12. |
| MX2009013431A (es) | 2007-06-18 | 2010-01-15 | Sanofi Aventis | Derivados de pirrol como antagonistas de p2y12. |
| CA2692153A1 (fr) | 2007-06-27 | 2009-01-08 | Richard W. Heidebrecht, Jr. | Derives pyridyles et pyrimidinyles en tant qu'inhibiteurs de l'histone desacetylase |
| US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| ES2371800T3 (es) | 2007-09-11 | 2012-01-10 | Kyorin Pharmaceutical Co.,Ltd. | Cianoaminoquinolonas como inhibidores de gsk-3. |
| BRPI0816814B1 (pt) | 2007-09-12 | 2021-08-31 | Kyorin Pharmaceutical Co. Ltd | Composto, composição farmacêutica e uso de um composto |
| RU2483072C2 (ru) * | 2007-11-29 | 2013-05-27 | Актелион Фармасьютиклз Лтд | Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12 |
| WO2010104205A1 (fr) | 2009-03-11 | 2010-09-16 | Kyorin Pharmaceutical Co., Ltd. | 7-cycloalkylaminoquinolones comme inhibiteurs de la gsk-3 |
| EP2821400B1 (fr) | 2009-03-20 | 2017-09-27 | Vertex Pharmaceuticals Incorporated | Procédé pour faire des modulateurs de régulateur de conductance transmembranaire de la fibrose kystique |
| US8134020B2 (en) * | 2009-12-10 | 2012-03-13 | The United States Of America As Represented By The Secretary Of The Army | Polymerization of hydroxytyrosol mediated by horseradish peroxidases |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| WO2012174013A2 (fr) * | 2011-06-14 | 2012-12-20 | Cardeus Pharmaceuticals, Inc. | Traitement d'une maladie cardiovasculaire, d'un accident vasculaire cérébral et d'états inflammatoires |
| WO2013033178A1 (fr) | 2011-08-30 | 2013-03-07 | University Of Utah Research Foundation | Procédés et compositions pour traiter le diabète insipide néphrogénique |
| WO2013130669A1 (fr) | 2012-02-27 | 2013-09-06 | Vertex Pharmaceuticals Incorporated | Composition pharmaceutique et son administration |
| TW201406758A (zh) * | 2012-06-28 | 2014-02-16 | Daiichi Sankyo Co Ltd | 三環性化合物 |
| AU2015330923B2 (en) | 2014-10-07 | 2020-03-12 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| CN107406390B (zh) * | 2014-11-17 | 2021-04-16 | 奈吉治疗公司 | 单羧酸转运蛋白调节剂及其用途 |
| US9382208B1 (en) | 2015-01-26 | 2016-07-05 | Vanderbilt University | Negative allosteric modulators of metabotropic glutamate receptor 2 |
| CN107949562B (zh) * | 2015-06-09 | 2021-07-23 | 拜耳制药股份公司 | 毒蕈碱性m2受体的正性变构调节剂 |
| CA3030204A1 (fr) | 2016-07-11 | 2018-01-18 | Bayer Pharma Aktiengesellschaft | Amides de l'acide 1-pyridyl-naphthyridin-3-carboxylique substitues en position 7, et leur utilisation |
| JOP20190045A1 (ar) * | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
| EP3296298A1 (fr) | 2016-09-14 | 2018-03-21 | Bayer Pharma Aktiengesellschaft | 1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation |
| TW202200547A (zh) * | 2020-03-13 | 2022-01-01 | 印度商卡地拉保健有限公司 | 喹啉酮化合物的新穎鹽類 |
| GB202015056D0 (en) | 2020-09-23 | 2020-11-04 | Cambridge Entpr Ltd | Biomarkers |
| CA3212004A1 (fr) * | 2021-03-19 | 2022-09-22 | Zydus Lifesciences Limited | Compose de quinolone sous formes solides et ses procedes de preparation |
| CN113461612B (zh) * | 2021-07-20 | 2022-10-14 | 上海应用技术大学 | 一种喹诺酮类端锚聚合酶2抑制剂及其制备方法和应用 |
| WO2023170724A1 (fr) * | 2022-03-08 | 2023-09-14 | The University Of Jordan | Utilisation de dérivés de quinolone substitués pour traiter le cancer |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1433774A (en) | 1973-02-26 | 1976-04-28 | Allen & Hanburys Ltd | Heterocyclic compounds apparatus for conveying articles |
| US4024255A (en) | 1973-04-05 | 1977-05-17 | Allen & Hanburys Limited | Tetrazole containing naphthyridine-3-carboxamides |
| GB1444369A (en) | 1973-04-05 | 1976-07-28 | Allen & Hanburys Ltd | 1,8-naphthyridines |
| US5106837A (en) | 1988-03-16 | 1992-04-21 | The Scripps Research Institute | Adenosine derivatives with therapeutic activity |
| US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US5324718A (en) | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| WO1994012181A1 (fr) | 1992-12-01 | 1994-06-09 | Merck & Co., Inc. | Antagonistes des recepteurs du fibrinogene |
| TW301607B (fr) * | 1993-03-09 | 1997-04-01 | Takeda Pharm Industry Co Ltd | |
| ATE239477T1 (de) | 1995-08-02 | 2003-05-15 | Darwin Discovery Ltd | Chinolone und deren therapeutische verwendung |
| AU695132B2 (en) | 1995-08-02 | 1998-08-06 | Darwin Discovery Limited | Quinolones and their therapeutic use |
| ATE342262T1 (de) * | 1996-11-27 | 2006-11-15 | Bristol Myers Squibb Pharma Co | Neue integrin rezeptor antagonisten |
| WO1998023592A1 (fr) | 1996-11-28 | 1998-06-04 | Wakunaga Pharmaceutical Co., Ltd. | Nouveaux derives d'acide pyridonecarboxylique ou leurs sels, et medicaments contenant ceux-ci en tant que principe actif |
| PL341364A1 (en) | 1997-12-22 | 2001-04-09 | Upjohn Co | 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents |
| US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
| US6248739B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
| US6248736B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents |
| TW500724B (en) | 1999-10-05 | 2002-09-01 | Pharmacia & Amp Upjohn Company | Oxazinoquinolones useful for the treatment of viral infections |
| CA2325358C (fr) | 1999-11-10 | 2005-08-02 | Pfizer Products Inc. | Amides de l'acide 7-¬(4'-trifluoromethylbiphenyl-2-carbonyl)amino|-quinoleine-3-carboxylique et methodes pour inhiber la secretion d'apolipoproteine b |
| US20020025961A1 (en) | 2000-02-04 | 2002-02-28 | Scarborough Robert M. | Platelet ADP receptor inhibitors |
| US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| JP2003531195A (ja) | 2000-03-21 | 2003-10-21 | ファルマシア・アンド・アップジョン・カンパニー | 抗ウイルス剤としての４−ヒドロキシシンノリン−３−カルボキサミド |
| US6682892B2 (en) | 2000-07-13 | 2004-01-27 | Pharmacia & Upjohn Company | Method for treating herpes viruses |
| GB2372986A (en) * | 2001-01-17 | 2002-09-11 | Xenova Ltd | 2-oxo, 4-hydroxy pyrroles and quinolines |
| JP2004520424A (ja) | 2001-03-01 | 2004-07-08 | ファルマシア・アンド・アップジョン・カンパニー | 抗ウイルス剤としての置換型キノリンカルボキサミド |
| SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
| US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| AU2002336462A1 (en) | 2001-09-06 | 2003-03-24 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US20040186131A1 (en) | 2002-08-30 | 2004-09-23 | Wathen Michael W | Method of preventing or treating atherosclerosis or restenosis |
| EP1650192A4 (fr) * | 2003-07-24 | 2007-03-21 | Astellas Pharma Inc | Derive de quinolone ou sel de ce dernier |
-
2004
- 2004-07-22 EP EP04748045A patent/EP1650192A4/fr not_active Withdrawn
- 2004-07-22 US US10/562,128 patent/US7488739B2/en not_active Expired - Fee Related
- 2004-07-22 KR KR1020067001356A patent/KR20060041254A/ko active IP Right Grant
- 2004-07-22 CN CNB2004800211878A patent/CN100471842C/zh not_active Expired - Fee Related
- 2004-07-22 WO PCT/JP2004/010781 patent/WO2005009971A1/fr not_active Application Discontinuation
- 2004-07-22 CA CA002530352A patent/CA2530352A1/fr not_active Abandoned
- 2004-07-22 MX MXPA06000675A patent/MXPA06000675A/es active IP Right Grant
-
2008
- 2008-12-31 US US12/347,428 patent/US7879878B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20060148806A1 (en) | 2006-07-06 |
| CA2530352A1 (fr) | 2005-02-03 |
| US20090124617A1 (en) | 2009-05-14 |
| MXPA06000675A (es) | 2006-04-19 |
| CN1826321A (zh) | 2006-08-30 |
| CN100471842C (zh) | 2009-03-25 |
| EP1650192A4 (fr) | 2007-03-21 |
| US7488739B2 (en) | 2009-02-10 |
| EP1650192A1 (fr) | 2006-04-26 |
| US7879878B2 (en) | 2011-02-01 |
| WO2005009971A1 (fr) | 2005-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20060041254A (ko) | 퀴놀론 유도체 또는 그의 염 | |
| JP5169821B2 (ja) | キノロン誘導体又はその製薬学的に許容される塩 | |
| JP6026441B2 (ja) | キナーゼ阻害剤としてのアミノキノリン | |
| JP2008094720A (ja) | キノロン誘導体のプロドラッグ又はその塩 | |
| JPWO2005080377A1 (ja) | ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 | |
| JP5856086B2 (ja) | 薬物製造のためのイソキノロン類の使用、新規なイソキノロン類およびそれらの合成方法 | |
| JP2013533316A (ja) | キナーゼ阻害剤としてのキノリルアミン | |
| TW201425307A (zh) | 作為激酶抑制劑之胺基－喹啉類 | |
| US9458135B2 (en) | Dihydroquinoline-2-one derivatives | |
| CZ20013660A3 (cs) | Substituované 3-kyano-(1,7),(1,5) a (1,8)-naftyridinové inhibitory tyrosinových kináz | |
| JPH05140162A (ja) | 精神的疾病を治療するための製薬学的調剤、ピリダジンジオン化合物および該化合物の製造法 | |
| JP4853824B2 (ja) | キノロン誘導体を有効成分とする医薬組成物 | |
| JP4858683B2 (ja) | キノロン誘導体又はその塩の製造法 | |
| TW200829568A (en) | Quinolone derivative or pharmaceutically acceptable salt thereof | |
| EP2970198B1 (fr) | Dérivés de dihydroquinoline-2-one à utiliser comme inhibiteurs de l'aldostérone synthase | |
| JP4725047B2 (ja) | キノロン誘導体又はその塩 | |
| JP2008266237A (ja) | 環状アミン誘導体又はその塩からなる医薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| NORF | Unpaid initial registration fee |